Abstract
seems to be important for the maintenance of both tein excretion were performed simultaneously 1 day before filter components [9, 10] . and 2 days after the first treatment cycle.
Patients and methods

Permselectivity studies
Iothalamate (as a measure of glomerular filtration rate, All patients with native kidney FSGS were resistant to GFR), neutral-dextran-and dextransulfate-clearance studies standard immunosuppressive therapy, including steroids, were performed before and after IAT as described in detail cyclophosphamide and cyclosporine A. Patients with recurelsewhere [8] . In summary the patients received an iothalarent FSGS in a transplant kidney were on triple-drug mate bolus followed by a constant infusion. A dextran immunosuppressive therapy.
40-dextran 70 mixture at a total dose of 130 mg dextran/kg Patient 1 was a 49-year-old woman who started IAT 34 bodyweight was used to determine size selectivity. Clearance months after the histological diagnosis of FSGS.
values for dextrans up to a molecular radius of 58 Å could Patient 2 was a 16-year-old girl. An initial biopsy perbe analysed in all patients. A bolus of tritiated dextransulfate formed because of massive nephrotic syndrome revealed was administered to quantify charge selectivity. The fracminimal-change glomerulonephritis. A second biopsy was tional clearance of each marker (Q M ) was calculated as the carried out 15 months later because of resistance to therapy clearance of each marker divided by the clearance of iothalaand FSGS was diagnosed. IAT was started 3 weeks later.
mate. Higher fractional clearance values indicate an impairPatient 3, a 23-year-old man, was also diagnosed initially ment of the respective permselectivity component. with minimal-change glomerulonephritis. FSGS was the diagnosis after the second biopsy 14 months later and IAT was initiated 8 months thereafter.
GVV studies
Patient 4 was a 29-year-old man who started IAT 48 months after FSGS was diagnosed.
The in vitro test for the presence of a factor altering glomerPatient 5 was a 25-year-old man with an 8-year medical ular albumin permeability in patient plasma was performed history of proteinuria. He refused diagnostic work up until as described by Godfrin et al. [4, 11] . Briefly glomeruli were severe nephrotic syndrome developed after an upper respirat-isolated from male Wistar rats (Charles River, St Elboeuf, ory tract infection. Biopsy revealed FSGS that was resistant France) and rinsed using an oxygenated isotonic R.P.M.I. to immunosuppressive treatment and IAT started 13 1640 solution (Gibco, Eragny, France) containing 6% BSA. months later.
The mean glomerular volume of approximately 1500 glomerPatient 6 lost native kidney function due to FSGS and uli was measured using a Multisizer counter (Coulter, Hileah, was on dialysis for 2 years. He received a cadaveric allograft FL). Afterwards glomeruli were incubated with patient sera and proteinuria developed within 4 weeks. A transplant and then exposed to hypo-oncotic stress (1% BSA). The biopsy carried out 4 weeks after engraftment established presence of the permeability factor increases albumin leakage recurrent disease and after an additional 3 months IAT out of the glomeruli and leads to a reduction in glomerular was started.
volume by concomitant water transfer. The glomerular Patient 7 was a 29-year-old man who reached end stage volume variation (GVV ) was defined as: renal failure 8 years after FSGS was diagnosed. After 2 years GVV (%)=1−(glomerular volume of test sample)/ on dialysis he received a cadaveric kidney transplant with immediate recurrence of proteinuria. Several rejection epis-(glomerular volume of control sample). odes had to be treated before IAT was initiated 5 months According to Godfrin et al.
[11] a variation in the glomerular later.
volume exceeding 3% was considered significant. The test Patient 8, a 43-year-old man, was on haemodialysis for 2 was carried out in triplicate using sera taken before and after months before he received a cadaveric renal allograft.
IAT in every patient and the calculated mean was used Proteinuria developed within 3 weeks and a biopsy was for analysis. finally performed after 5 months showing characteristic feaStatistical analysis was carried out using Student's t-test tures of FSGS. IAT began 2 months later.
for paired data. All values are given as means±1 SEM. The study was approved by the local human subjects committee.
Immunadsorption procedures
Six patients were treated with protein-A and 2 (Patients 5 Results and 8) with IgG immunadsorption. After primary plasma separation with the autopheresis-CTM TPS (Therapeutic As can be seen from Table 1, immunadsorption therapy Plasma System, Baxter, IL) at each session, 2.5 plasma volumes were run at a flow rate of 35 ml/min over two reduced serum IgG, IgM, IgA and immunoglobulin cartridges containing 62.5 ml of SPA (Immuno-adsorba, light chain concentrations in all patients. Individual Excorim, Sweden) or an anti-IgG antibody (Ig-Therasorb, data on GFR, 24-h urinary protein excretion and the Munich, Germany). After plasma loading, the columns were values for the fractional protein excretion, the fracflushed with sodium citrate at a pH of 2.2 (SPA column) or tional clearance of 58 Å neutral dextran and dexwith a 0.2 M glycin HCl buffer at a pH of 2.8 (IgG transulfate before and after the first cycle, are given in adsorption). Finally the columns were flushed with PBS Table 2 . Proteinuria was reduced by 50% or more in 4 (pH 7.2) and 0.9% NaCl solution. One cycle of therapy patients (1, 5, 6 and 7). This decrease was not due to consisted of five treatment sessions within 10 days. If no a reduction in serum protein concentrations by IAT as response was obtained (defined as a reduction of proteinuria evidenced by a reduction in the fractional protein >50%) the cycle was repeated after 1 week. However, patients resistant to one cycle remained unresponsive. excretion. Mean GFR and urinary protein excretion for all was repeated successfully in all but one patient. Patient 1 had been on IAT for 1.5 years when a stable remission eight patients did not change significantly during the study (61±17 ml/min vs 61±13 ml/min and of proteinuria was achieved. In patient 5, proteinuria increased 1 month after therapy and was then resistant 11.5±2.9 g/day vs 8.7±3.3 g/day before and after IAT, respectively). Immunadsorption significantly reduced to further intervention. Patient 7 lost his graft 3 months after the initiation of IAT due graft rejection. Patient the mean fractional clearance of 58 Å neutral dextrans (Q D58 0.0133±0.0045 before vs 0.009±0.0047 after 6 has now been treated for almost 2 years and his fractional protein excretion has been reduced by an therapy) mainly due to a dramatic improvement in glomerular size selectivity in responsive patients. The order of magnitude. differences in fractional clearance values for smaller dextran molecules were not statistically significant Discussion between the two groups at any time. Charge selectivity improved in both patients with a positive pre-treatment GVV-test and in one additional patient; however, for Primary FSGS is characterized clinically by nephrotic range proteinuria and histologically by solidification the patient as a whole group no significant change in the fractional clearance of dextransulfate was noted of the glomerular tuft and obliteration of the glomerular capillary lumen by a relatively acellular matrix (Q DS 0.68±0.073 before vs 0.54±0.046 after IAT ). Two patients (5 and 7) had a positive and 6 a negative material on light-microscopy, and by diffuse epithelial foot process fusion on electron-microscopy. The glom-GVV-test before the first session of immunadsorption. When the test was carried out using sera obtained after erular epithelial cell is considered to be the common primary target of injury and it is likely that a variety the first treatment cycle GVV decreased to 0% in the previously positive patients and remained negative in of different pathogenetic factors lead to the same histopathological pattern. It has been suggested that the others ( Table 2) .
In patients responsive to IAT proteinuria relapsed in some patients a circulating factor might be responsible for podocyte damage as early proteinuria after after a mean of 21 days, at which time the treatment
